These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9786731)

  • 21. Efficacy of alpha 2b versus lymphoblastoid interferon in treatment of chronic hepatitis C. A randomized trial.
    González Sánchez M; Palacios A; Caballero T; Torres Fernández-Piñar C; Bellot V; Ruiz Extremera A; Salmerón J
    Rev Esp Enferm Dig; 1998 Aug; 90(8):553-62. PubMed ID: 9780788
    [No Abstract]   [Full Text] [Related]  

  • 22. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C.
    Downs AM; Dunnill MG
    Clin Exp Dermatol; 2000 Jun; 25(4):351-2. PubMed ID: 10971502
    [No Abstract]   [Full Text] [Related]  

  • 23. Characteristics of chronic hepatitis C and response to interferon therapy in older patients.
    Hervé S; Savoye G; Riachi G; Capet C; Goria O; Lerebours E; Colin R
    Age Ageing; 2001 Jul; 30(4):355-6. PubMed ID: 11509317
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon alfa for chronic hepatitis C infection.
    Kingsley D
    Lancet; 1999 Feb; 353(9151):499; author reply 500. PubMed ID: 9989746
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness in hepatitis B.
    Weitzman G; Jacobson I
    Ann Intern Med; 2005 Nov; 143(10):757-8; author reply 758-9. PubMed ID: 16287803
    [No Abstract]   [Full Text] [Related]  

  • 26. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
    Wong JB; Koff RS; Tinè F; Pauker SG
    Ann Intern Med; 1995 May; 122(9):664-75. PubMed ID: 7702228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
    Schalm SW
    Gut; 1998 Nov; 43(5):602. PubMed ID: 9824337
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination therapy for hepatitis C infection.
    Newman TB
    N Engl J Med; 1999 Apr; 340(15):1207; author reply 1208-9. PubMed ID: 10206843
    [No Abstract]   [Full Text] [Related]  

  • 32. Case report: a patient who developed an amoebic liver abscess during treatment with interferon.
    Matsuo T; Shinzawa H; Sugahara K; Mitsuhashi H; Watanabe H; Abe T; Ohno S; Terashita M; Saito K; Saito T; Misawa H; Togashi H; Takahashi T
    J Gastroenterol Hepatol; 1998 Oct; 13(10):1068-71. PubMed ID: 9835326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of interferon in chronic active hepatitis C.
    Turnbull C; Sugano D
    Med J Aust; 1994 Jul; 161(2):169; author reply 170. PubMed ID: 8028544
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
    Brown JL
    Lancet; 1998 Jan; 351(9096):78-9. PubMed ID: 9439486
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Arguedas M
    Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical guidelines on the management of hepatitis C.
    Booth JC; O'Grady J; Neuberger J;
    Gut; 2001 Jul; 49 Suppl 1(Suppl 1):I1-21. PubMed ID: 11413125
    [No Abstract]   [Full Text] [Related]  

  • 37. New interferon alfa formulation licensed for treatment of hepatitis C.
    Thompson CA
    Am J Health Syst Pharm; 2001 Mar; 58(6):452. PubMed ID: 11286138
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].
    Buti M; Casado MA; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 1998 Apr; 21(4):161-8. PubMed ID: 9633175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre randomized controlled trial of recombinant interferon-alpha-2a in the treatment of patients with chronic hepatitis C.
    Komatsu M; Ono T; Nakajima K; Toyoshima I; Chiba M; Masamune O; Ohkubo S; Yoshida T; Yagisawa H; Komatsu K; Wakamatsu H; Yamada N; Watanabe H; Mukojima T; Goto M
    Can J Gastroenterol; 1997 Oct; 11(7):579-82. PubMed ID: 9395758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.